nodes	percent_of_prediction	percent_of_DWPC	metapath
Mesalazine—ALOX5—hematologic cancer	0.191	0.608	CbGaD
Mesalazine—L-DOPA—Melphalan—hematologic cancer	0.125	1	CrCrCtD
Mesalazine—MPO—hematologic cancer	0.123	0.392	CbGaD
Mesalazine—PTGS2—Lenalidomide—hematologic cancer	0.0435	0.183	CbGbCtD
Mesalazine—MPO—Cisplatin—hematologic cancer	0.0288	0.121	CbGbCtD
Mesalazine—PTGS2—Thalidomide—hematologic cancer	0.0232	0.0979	CbGbCtD
Mesalazine—PTGS1—Bortezomib—hematologic cancer	0.0225	0.0949	CbGbCtD
Mesalazine—PTGS1—Thalidomide—hematologic cancer	0.0196	0.0826	CbGbCtD
Mesalazine—PTGS1—Ifosfamide—hematologic cancer	0.0173	0.0728	CbGbCtD
Mesalazine—PTGS1—Imatinib—hematologic cancer	0.0165	0.0695	CbGbCtD
Mesalazine—PTGS2—Triamcinolone—hematologic cancer	0.0161	0.0678	CbGbCtD
Mesalazine—PTGS2—Betamethasone—hematologic cancer	0.0138	0.0582	CbGbCtD
Mesalazine—PTGS2—Cisplatin—hematologic cancer	0.00995	0.0419	CbGbCtD
Mesalazine—PTGS2—Etoposide—hematologic cancer	0.00977	0.0412	CbGbCtD
Mesalazine—PTGS1—Etoposide—hematologic cancer	0.00825	0.0348	CbGbCtD
Mesalazine—PTGS2—Dexamethasone—hematologic cancer	0.00804	0.0339	CbGbCtD
Mesalazine—PTGS2—ovarian follicle—hematologic cancer	0.00396	0.122	CbGeAlD
Mesalazine—CHUK—hematopoietic system—hematologic cancer	0.00221	0.068	CbGeAlD
Mesalazine—IKBKB—hematopoietic system—hematologic cancer	0.0015	0.0463	CbGeAlD
Mesalazine—CHUK—blood—hematologic cancer	0.00147	0.0451	CbGeAlD
Mesalazine—CHUK—lung—hematologic cancer	0.00129	0.0395	CbGeAlD
Mesalazine—ALOX5—hematopoietic system—hematologic cancer	0.00125	0.0383	CbGeAlD
Mesalazine—CHUK—testis—hematologic cancer	0.00121	0.0373	CbGeAlD
Mesalazine—IKBKB—gonad—hematologic cancer	0.00114	0.0352	CbGeAlD
Mesalazine—MPO—hematopoietic system—hematologic cancer	0.00105	0.0324	CbGeAlD
Mesalazine—IKBKB—blood—hematologic cancer	0.000996	0.0306	CbGeAlD
Mesalazine—L-DOPA—PSIP1—hematologic cancer	0.00098	0.373	CrCbGaD
Mesalazine—PPARG—hematopoietic system—hematologic cancer	0.000936	0.0288	CbGeAlD
Mesalazine—CHUK—lymph node—hematologic cancer	0.000879	0.027	CbGeAlD
Mesalazine—IKBKB—lung—hematologic cancer	0.000873	0.0269	CbGeAlD
Mesalazine—ALOX5—blood—hematologic cancer	0.000826	0.0254	CbGeAlD
Mesalazine—IKBKB—testis—hematologic cancer	0.000824	0.0253	CbGeAlD
Mesalazine—ALOX5—bone marrow—hematologic cancer	0.000799	0.0246	CbGeAlD
Mesalazine—ALOX5—lung—hematologic cancer	0.000724	0.0223	CbGeAlD
Mesalazine—MPO—blood—hematologic cancer	0.000699	0.0215	CbGeAlD
Mesalazine—ALOX5—testis—hematologic cancer	0.000683	0.021	CbGeAlD
Mesalazine—MPO—bone marrow—hematologic cancer	0.000676	0.0208	CbGeAlD
Mesalazine—PPARG—blood—hematologic cancer	0.00062	0.0191	CbGeAlD
Mesalazine—MPO—lung—hematologic cancer	0.000613	0.0188	CbGeAlD
Mesalazine—PPARG—bone marrow—hematologic cancer	0.0006	0.0185	CbGeAlD
Mesalazine—IKBKB—lymph node—hematologic cancer	0.000597	0.0184	CbGeAlD
Mesalazine—MPO—testis—hematologic cancer	0.000578	0.0178	CbGeAlD
Mesalazine—PPARG—lung—hematologic cancer	0.000544	0.0167	CbGeAlD
Mesalazine—PPARG—Ponatinib—Nilotinib—hematologic cancer	0.00054	0.24	CbGdCrCtD
Mesalazine—PPARG—testis—hematologic cancer	0.000513	0.0158	CbGeAlD
Mesalazine—PTGS1—hematopoietic system—hematologic cancer	0.0005	0.0154	CbGeAlD
Mesalazine—ALOX5—lymph node—hematologic cancer	0.000495	0.0152	CbGeAlD
Mesalazine—PTGS2—hematopoietic system—hematologic cancer	0.000478	0.0147	CbGeAlD
Mesalazine—Olsalazine—IFNG—hematologic cancer	0.000445	0.169	CrCbGaD
Mesalazine—MPO—lymph node—hematologic cancer	0.000419	0.0129	CbGeAlD
Mesalazine—PPARG—Ponatinib—Imatinib—hematologic cancer	0.000409	0.182	CbGdCrCtD
Mesalazine—PPARG—Topotecan—Irinotecan—hematologic cancer	0.000388	0.172	CbGdCrCtD
Mesalazine—PPARG—Etoposide—Teniposide—hematologic cancer	0.000385	0.171	CbGdCrCtD
Mesalazine—PPARG—lymph node—hematologic cancer	0.000372	0.0114	CbGeAlD
Mesalazine—Olsalazine—ALOX5—hematologic cancer	0.000367	0.14	CrCbGaD
Mesalazine—Aminosalicylic Acid—ALOX5—hematologic cancer	0.000345	0.131	CrCbGaD
Mesalazine—PTGS1—blood—hematologic cancer	0.000331	0.0102	CbGeAlD
Mesalazine—PTGS2—blood—hematologic cancer	0.000317	0.00974	CbGeAlD
Mesalazine—PTGS2—bone marrow—hematologic cancer	0.000307	0.00943	CbGeAlD
Mesalazine—PTGS1—lung—hematologic cancer	0.000291	0.00894	CbGeAlD
Mesalazine—PTGS2—lung—hematologic cancer	0.000278	0.00854	CbGeAlD
Mesalazine—PTGS1—testis—hematologic cancer	0.000274	0.00843	CbGeAlD
Mesalazine—Aminosalicylic Acid—MPO—hematologic cancer	0.000222	0.0846	CrCbGaD
Mesalazine—PTGS1—lymph node—hematologic cancer	0.000199	0.00611	CbGeAlD
Mesalazine—PTGS2—lymph node—hematologic cancer	0.00019	0.00584	CbGeAlD
Mesalazine—PPARG—Teniposide—Etoposide—hematologic cancer	0.000175	0.0777	CbGdCrCtD
Mesalazine—Dopamine—SLC22A1—hematologic cancer	0.000113	0.0429	CrCbGaD
Mesalazine—Diflunisal—ALB—hematologic cancer	7.42e-05	0.0282	CrCbGaD
Mesalazine—PTGS2—Fluocinonide—Betamethasone—hematologic cancer	7.4e-05	0.0329	CbGdCrCtD
Mesalazine—PTGS2—Fluocinonide—Dexamethasone—hematologic cancer	7.4e-05	0.0329	CbGdCrCtD
Mesalazine—PTGS2—Fluocinonide—Triamcinolone—hematologic cancer	7.23e-05	0.0321	CbGdCrCtD
Mesalazine—PTGS2—Fluticasone Propionate—Dexamethasone—hematologic cancer	4.46e-05	0.0198	CbGdCrCtD
Mesalazine—PTGS2—Fluticasone Propionate—Betamethasone—hematologic cancer	4.46e-05	0.0198	CbGdCrCtD
Mesalazine—PTGS2—Fluticasone Propionate—Triamcinolone—hematologic cancer	4.36e-05	0.0194	CbGdCrCtD
Mesalazine—Salicylic acid—ALB—hematologic cancer	4.13e-05	0.0157	CrCbGaD
Mesalazine—Salicylic acid—ABCB1—hematologic cancer	3.94e-05	0.015	CrCbGaD
Mesalazine—Eye disorder—Doxorubicin—hematologic cancer	7.17e-06	4.19e-05	CcSEcCtD
Mesalazine—Ill-defined disorder—Methotrexate—hematologic cancer	7.16e-06	4.18e-05	CcSEcCtD
Mesalazine—Tinnitus—Doxorubicin—hematologic cancer	7.16e-06	4.18e-05	CcSEcCtD
Mesalazine—Anaemia—Methotrexate—hematologic cancer	7.13e-06	4.16e-05	CcSEcCtD
Mesalazine—Feeling abnormal—Betamethasone—hematologic cancer	7.13e-06	4.16e-05	CcSEcCtD
Mesalazine—Feeling abnormal—Dexamethasone—hematologic cancer	7.13e-06	4.16e-05	CcSEcCtD
Mesalazine—Cardiac disorder—Doxorubicin—hematologic cancer	7.12e-06	4.16e-05	CcSEcCtD
Mesalazine—Flatulence—Epirubicin—hematologic cancer	7.11e-06	4.15e-05	CcSEcCtD
Mesalazine—Tension—Epirubicin—hematologic cancer	7.09e-06	4.14e-05	CcSEcCtD
Mesalazine—Gastrointestinal pain—Dexamethasone—hematologic cancer	7.07e-06	4.13e-05	CcSEcCtD
Mesalazine—Gastrointestinal pain—Betamethasone—hematologic cancer	7.07e-06	4.13e-05	CcSEcCtD
Mesalazine—Dysgeusia—Epirubicin—hematologic cancer	7.07e-06	4.13e-05	CcSEcCtD
Mesalazine—Hypersensitivity—Triamcinolone—hematologic cancer	7.02e-06	4.1e-05	CcSEcCtD
Mesalazine—Nervousness—Epirubicin—hematologic cancer	7.01e-06	4.09e-05	CcSEcCtD
Mesalazine—Back pain—Epirubicin—hematologic cancer	6.98e-06	4.08e-05	CcSEcCtD
Mesalazine—Angiopathy—Doxorubicin—hematologic cancer	6.96e-06	4.06e-05	CcSEcCtD
Mesalazine—Malaise—Methotrexate—hematologic cancer	6.96e-06	4.06e-05	CcSEcCtD
Mesalazine—Dizziness—Etoposide—hematologic cancer	6.95e-06	4.06e-05	CcSEcCtD
Mesalazine—Muscle spasms—Epirubicin—hematologic cancer	6.94e-06	4.05e-05	CcSEcCtD
Mesalazine—Immune system disorder—Doxorubicin—hematologic cancer	6.93e-06	4.05e-05	CcSEcCtD
Mesalazine—Vertigo—Methotrexate—hematologic cancer	6.93e-06	4.05e-05	CcSEcCtD
Mesalazine—Mediastinal disorder—Doxorubicin—hematologic cancer	6.92e-06	4.04e-05	CcSEcCtD
Mesalazine—Leukopenia—Methotrexate—hematologic cancer	6.91e-06	4.03e-05	CcSEcCtD
Mesalazine—Chills—Doxorubicin—hematologic cancer	6.89e-06	4.02e-05	CcSEcCtD
Mesalazine—Urticaria—Betamethasone—hematologic cancer	6.87e-06	4.01e-05	CcSEcCtD
Mesalazine—Urticaria—Dexamethasone—hematologic cancer	6.87e-06	4.01e-05	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Prednisone—hematologic cancer	6.86e-06	4.01e-05	CcSEcCtD
Mesalazine—Dizziness—Prednisolone—hematologic cancer	6.86e-06	4e-05	CcSEcCtD
Mesalazine—Asthenia—Triamcinolone—hematologic cancer	6.84e-06	3.99e-05	CcSEcCtD
Mesalazine—Body temperature increased—Dexamethasone—hematologic cancer	6.84e-06	3.99e-05	CcSEcCtD
Mesalazine—Body temperature increased—Betamethasone—hematologic cancer	6.84e-06	3.99e-05	CcSEcCtD
Mesalazine—Abdominal pain—Betamethasone—hematologic cancer	6.84e-06	3.99e-05	CcSEcCtD
Mesalazine—Abdominal pain—Dexamethasone—hematologic cancer	6.84e-06	3.99e-05	CcSEcCtD
Mesalazine—Nausea—Cisplatin—hematologic cancer	6.82e-06	3.98e-05	CcSEcCtD
Mesalazine—Insomnia—Prednisone—hematologic cancer	6.81e-06	3.98e-05	CcSEcCtD
Mesalazine—Vision blurred—Epirubicin—hematologic cancer	6.8e-06	3.97e-05	CcSEcCtD
Mesalazine—Alopecia—Doxorubicin—hematologic cancer	6.78e-06	3.96e-05	CcSEcCtD
Mesalazine—Paraesthesia—Prednisone—hematologic cancer	6.77e-06	3.95e-05	CcSEcCtD
Mesalazine—Pruritus—Triamcinolone—hematologic cancer	6.75e-06	3.94e-05	CcSEcCtD
Mesalazine—Cough—Methotrexate—hematologic cancer	6.73e-06	3.93e-05	CcSEcCtD
Mesalazine—Mental disorder—Doxorubicin—hematologic cancer	6.72e-06	3.92e-05	CcSEcCtD
Mesalazine—Ill-defined disorder—Epirubicin—hematologic cancer	6.7e-06	3.91e-05	CcSEcCtD
Mesalazine—Vomiting—Etoposide—hematologic cancer	6.68e-06	3.9e-05	CcSEcCtD
Mesalazine—Erythema—Doxorubicin—hematologic cancer	6.68e-06	3.9e-05	CcSEcCtD
Mesalazine—Anaemia—Epirubicin—hematologic cancer	6.67e-06	3.9e-05	CcSEcCtD
Mesalazine—Dyspepsia—Prednisone—hematologic cancer	6.63e-06	3.87e-05	CcSEcCtD
Mesalazine—Rash—Etoposide—hematologic cancer	6.63e-06	3.87e-05	CcSEcCtD
Mesalazine—Dermatitis—Etoposide—hematologic cancer	6.62e-06	3.87e-05	CcSEcCtD
Mesalazine—Headache—Etoposide—hematologic cancer	6.59e-06	3.84e-05	CcSEcCtD
Mesalazine—Flatulence—Doxorubicin—hematologic cancer	6.58e-06	3.84e-05	CcSEcCtD
Mesalazine—Chest pain—Methotrexate—hematologic cancer	6.57e-06	3.83e-05	CcSEcCtD
Mesalazine—Arthralgia—Methotrexate—hematologic cancer	6.57e-06	3.83e-05	CcSEcCtD
Mesalazine—Myalgia—Methotrexate—hematologic cancer	6.57e-06	3.83e-05	CcSEcCtD
Mesalazine—Tension—Doxorubicin—hematologic cancer	6.56e-06	3.83e-05	CcSEcCtD
Mesalazine—Decreased appetite—Prednisone—hematologic cancer	6.55e-06	3.82e-05	CcSEcCtD
Mesalazine—Dysgeusia—Doxorubicin—hematologic cancer	6.54e-06	3.82e-05	CcSEcCtD
Mesalazine—Rash—Prednisolone—hematologic cancer	6.54e-06	3.82e-05	CcSEcCtD
Mesalazine—Dermatitis—Prednisolone—hematologic cancer	6.53e-06	3.81e-05	CcSEcCtD
Mesalazine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	6.52e-06	3.81e-05	CcSEcCtD
Mesalazine—Malaise—Epirubicin—hematologic cancer	6.51e-06	3.8e-05	CcSEcCtD
Mesalazine—Fatigue—Prednisone—hematologic cancer	6.5e-06	3.79e-05	CcSEcCtD
Mesalazine—Headache—Prednisolone—hematologic cancer	6.5e-06	3.79e-05	CcSEcCtD
Mesalazine—Discomfort—Methotrexate—hematologic cancer	6.49e-06	3.79e-05	CcSEcCtD
Mesalazine—Nervousness—Doxorubicin—hematologic cancer	6.49e-06	3.79e-05	CcSEcCtD
Mesalazine—Vertigo—Epirubicin—hematologic cancer	6.49e-06	3.79e-05	CcSEcCtD
Mesalazine—Syncope—Epirubicin—hematologic cancer	6.47e-06	3.78e-05	CcSEcCtD
Mesalazine—Leukopenia—Epirubicin—hematologic cancer	6.46e-06	3.77e-05	CcSEcCtD
Mesalazine—Back pain—Doxorubicin—hematologic cancer	6.46e-06	3.77e-05	CcSEcCtD
Mesalazine—Constipation—Prednisone—hematologic cancer	6.44e-06	3.76e-05	CcSEcCtD
Mesalazine—Muscle spasms—Doxorubicin—hematologic cancer	6.42e-06	3.75e-05	CcSEcCtD
Mesalazine—Palpitations—Epirubicin—hematologic cancer	6.38e-06	3.72e-05	CcSEcCtD
Mesalazine—Confusional state—Methotrexate—hematologic cancer	6.35e-06	3.71e-05	CcSEcCtD
Mesalazine—Loss of consciousness—Epirubicin—hematologic cancer	6.35e-06	3.7e-05	CcSEcCtD
Mesalazine—Dizziness—Triamcinolone—hematologic cancer	6.31e-06	3.68e-05	CcSEcCtD
Mesalazine—Cough—Epirubicin—hematologic cancer	6.3e-06	3.68e-05	CcSEcCtD
Mesalazine—Anaphylactic shock—Methotrexate—hematologic cancer	6.3e-06	3.68e-05	CcSEcCtD
Mesalazine—Vision blurred—Doxorubicin—hematologic cancer	6.3e-06	3.67e-05	CcSEcCtD
Mesalazine—Infection—Methotrexate—hematologic cancer	6.26e-06	3.65e-05	CcSEcCtD
Mesalazine—Nausea—Etoposide—hematologic cancer	6.24e-06	3.64e-05	CcSEcCtD
Mesalazine—Hypertension—Epirubicin—hematologic cancer	6.23e-06	3.64e-05	CcSEcCtD
Mesalazine—Feeling abnormal—Prednisone—hematologic cancer	6.21e-06	3.62e-05	CcSEcCtD
Mesalazine—Asthenia—Betamethasone—hematologic cancer	6.21e-06	3.62e-05	CcSEcCtD
Mesalazine—Asthenia—Dexamethasone—hematologic cancer	6.21e-06	3.62e-05	CcSEcCtD
Mesalazine—Ill-defined disorder—Doxorubicin—hematologic cancer	6.2e-06	3.62e-05	CcSEcCtD
Mesalazine—Nervous system disorder—Methotrexate—hematologic cancer	6.17e-06	3.6e-05	CcSEcCtD
Mesalazine—Anaemia—Doxorubicin—hematologic cancer	6.17e-06	3.6e-05	CcSEcCtD
Mesalazine—Thrombocytopenia—Methotrexate—hematologic cancer	6.16e-06	3.6e-05	CcSEcCtD
Mesalazine—Gastrointestinal pain—Prednisone—hematologic cancer	6.16e-06	3.6e-05	CcSEcCtD
Mesalazine—Nausea—Prednisolone—hematologic cancer	6.16e-06	3.59e-05	CcSEcCtD
Mesalazine—Chest pain—Epirubicin—hematologic cancer	6.15e-06	3.59e-05	CcSEcCtD
Mesalazine—Arthralgia—Epirubicin—hematologic cancer	6.15e-06	3.59e-05	CcSEcCtD
Mesalazine—Myalgia—Epirubicin—hematologic cancer	6.15e-06	3.59e-05	CcSEcCtD
Mesalazine—Anxiety—Epirubicin—hematologic cancer	6.13e-06	3.58e-05	CcSEcCtD
Mesalazine—Pruritus—Dexamethasone—hematologic cancer	6.12e-06	3.57e-05	CcSEcCtD
Mesalazine—Pruritus—Betamethasone—hematologic cancer	6.12e-06	3.57e-05	CcSEcCtD
Mesalazine—Skin disorder—Methotrexate—hematologic cancer	6.12e-06	3.57e-05	CcSEcCtD
Mesalazine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	6.1e-06	3.56e-05	CcSEcCtD
Mesalazine—Hyperhidrosis—Methotrexate—hematologic cancer	6.09e-06	3.55e-05	CcSEcCtD
Mesalazine—Discomfort—Epirubicin—hematologic cancer	6.07e-06	3.54e-05	CcSEcCtD
Mesalazine—Vomiting—Triamcinolone—hematologic cancer	6.06e-06	3.54e-05	CcSEcCtD
Mesalazine—Malaise—Doxorubicin—hematologic cancer	6.02e-06	3.52e-05	CcSEcCtD
Mesalazine—Rash—Triamcinolone—hematologic cancer	6.01e-06	3.51e-05	CcSEcCtD
Mesalazine—Dry mouth—Epirubicin—hematologic cancer	6.01e-06	3.51e-05	CcSEcCtD
Mesalazine—Dermatitis—Triamcinolone—hematologic cancer	6.01e-06	3.51e-05	CcSEcCtD
Mesalazine—Vertigo—Doxorubicin—hematologic cancer	6e-06	3.5e-05	CcSEcCtD
Mesalazine—Anorexia—Methotrexate—hematologic cancer	6e-06	3.5e-05	CcSEcCtD
Mesalazine—Syncope—Doxorubicin—hematologic cancer	5.99e-06	3.5e-05	CcSEcCtD
Mesalazine—Urticaria—Prednisone—hematologic cancer	5.99e-06	3.49e-05	CcSEcCtD
Mesalazine—Leukopenia—Doxorubicin—hematologic cancer	5.98e-06	3.49e-05	CcSEcCtD
Mesalazine—Headache—Triamcinolone—hematologic cancer	5.97e-06	3.49e-05	CcSEcCtD
Mesalazine—Abdominal pain—Prednisone—hematologic cancer	5.96e-06	3.48e-05	CcSEcCtD
Mesalazine—Body temperature increased—Prednisone—hematologic cancer	5.96e-06	3.48e-05	CcSEcCtD
Mesalazine—Confusional state—Epirubicin—hematologic cancer	5.94e-06	3.47e-05	CcSEcCtD
Mesalazine—Diarrhoea—Betamethasone—hematologic cancer	5.92e-06	3.46e-05	CcSEcCtD
Mesalazine—Diarrhoea—Dexamethasone—hematologic cancer	5.92e-06	3.46e-05	CcSEcCtD
Mesalazine—Palpitations—Doxorubicin—hematologic cancer	5.9e-06	3.45e-05	CcSEcCtD
Mesalazine—Anaphylactic shock—Epirubicin—hematologic cancer	5.89e-06	3.44e-05	CcSEcCtD
Mesalazine—Oedema—Epirubicin—hematologic cancer	5.89e-06	3.44e-05	CcSEcCtD
Mesalazine—Hypotension—Methotrexate—hematologic cancer	5.88e-06	3.43e-05	CcSEcCtD
Mesalazine—Loss of consciousness—Doxorubicin—hematologic cancer	5.87e-06	3.43e-05	CcSEcCtD
Mesalazine—Infection—Epirubicin—hematologic cancer	5.85e-06	3.42e-05	CcSEcCtD
Mesalazine—Cough—Doxorubicin—hematologic cancer	5.83e-06	3.4e-05	CcSEcCtD
Mesalazine—Shock—Epirubicin—hematologic cancer	5.8e-06	3.38e-05	CcSEcCtD
Mesalazine—Nervous system disorder—Epirubicin—hematologic cancer	5.78e-06	3.37e-05	CcSEcCtD
Mesalazine—Thrombocytopenia—Epirubicin—hematologic cancer	5.77e-06	3.37e-05	CcSEcCtD
Mesalazine—Hypertension—Doxorubicin—hematologic cancer	5.77e-06	3.37e-05	CcSEcCtD
Mesalazine—Tachycardia—Epirubicin—hematologic cancer	5.75e-06	3.36e-05	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Methotrexate—hematologic cancer	5.74e-06	3.35e-05	CcSEcCtD
Mesalazine—Skin disorder—Epirubicin—hematologic cancer	5.72e-06	3.34e-05	CcSEcCtD
Mesalazine—Dizziness—Dexamethasone—hematologic cancer	5.72e-06	3.34e-05	CcSEcCtD
Mesalazine—Dizziness—Betamethasone—hematologic cancer	5.72e-06	3.34e-05	CcSEcCtD
Mesalazine—Hyperhidrosis—Epirubicin—hematologic cancer	5.7e-06	3.33e-05	CcSEcCtD
Mesalazine—Insomnia—Methotrexate—hematologic cancer	5.69e-06	3.32e-05	CcSEcCtD
Mesalazine—Arthralgia—Doxorubicin—hematologic cancer	5.69e-06	3.32e-05	CcSEcCtD
Mesalazine—Chest pain—Doxorubicin—hematologic cancer	5.69e-06	3.32e-05	CcSEcCtD
Mesalazine—Myalgia—Doxorubicin—hematologic cancer	5.69e-06	3.32e-05	CcSEcCtD
Mesalazine—Anxiety—Doxorubicin—hematologic cancer	5.67e-06	3.31e-05	CcSEcCtD
Mesalazine—Nausea—Triamcinolone—hematologic cancer	5.66e-06	3.31e-05	CcSEcCtD
Mesalazine—Paraesthesia—Methotrexate—hematologic cancer	5.65e-06	3.3e-05	CcSEcCtD
Mesalazine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	5.65e-06	3.3e-05	CcSEcCtD
Mesalazine—Discomfort—Doxorubicin—hematologic cancer	5.62e-06	3.28e-05	CcSEcCtD
Mesalazine—Anorexia—Epirubicin—hematologic cancer	5.62e-06	3.28e-05	CcSEcCtD
Mesalazine—Dyspnoea—Methotrexate—hematologic cancer	5.61e-06	3.28e-05	CcSEcCtD
Mesalazine—Somnolence—Methotrexate—hematologic cancer	5.6e-06	3.27e-05	CcSEcCtD
Mesalazine—Dry mouth—Doxorubicin—hematologic cancer	5.56e-06	3.25e-05	CcSEcCtD
Mesalazine—Hypersensitivity—Prednisone—hematologic cancer	5.55e-06	3.24e-05	CcSEcCtD
Mesalazine—Dyspepsia—Methotrexate—hematologic cancer	5.54e-06	3.24e-05	CcSEcCtD
Mesalazine—Hypotension—Epirubicin—hematologic cancer	5.51e-06	3.21e-05	CcSEcCtD
Mesalazine—Vomiting—Dexamethasone—hematologic cancer	5.5e-06	3.21e-05	CcSEcCtD
Mesalazine—Vomiting—Betamethasone—hematologic cancer	5.5e-06	3.21e-05	CcSEcCtD
Mesalazine—Confusional state—Doxorubicin—hematologic cancer	5.5e-06	3.21e-05	CcSEcCtD
Mesalazine—Decreased appetite—Methotrexate—hematologic cancer	5.47e-06	3.19e-05	CcSEcCtD
Mesalazine—Rash—Dexamethasone—hematologic cancer	5.45e-06	3.18e-05	CcSEcCtD
Mesalazine—Rash—Betamethasone—hematologic cancer	5.45e-06	3.18e-05	CcSEcCtD
Mesalazine—Anaphylactic shock—Doxorubicin—hematologic cancer	5.45e-06	3.18e-05	CcSEcCtD
Mesalazine—Oedema—Doxorubicin—hematologic cancer	5.45e-06	3.18e-05	CcSEcCtD
Mesalazine—Dermatitis—Betamethasone—hematologic cancer	5.45e-06	3.18e-05	CcSEcCtD
Mesalazine—Dermatitis—Dexamethasone—hematologic cancer	5.45e-06	3.18e-05	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Methotrexate—hematologic cancer	5.44e-06	3.17e-05	CcSEcCtD
Mesalazine—Fatigue—Methotrexate—hematologic cancer	5.43e-06	3.17e-05	CcSEcCtD
Mesalazine—Headache—Betamethasone—hematologic cancer	5.42e-06	3.16e-05	CcSEcCtD
Mesalazine—Headache—Dexamethasone—hematologic cancer	5.42e-06	3.16e-05	CcSEcCtD
Mesalazine—Infection—Doxorubicin—hematologic cancer	5.42e-06	3.16e-05	CcSEcCtD
Mesalazine—Asthenia—Prednisone—hematologic cancer	5.41e-06	3.16e-05	CcSEcCtD
Mesalazine—Pain—Methotrexate—hematologic cancer	5.38e-06	3.14e-05	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Epirubicin—hematologic cancer	5.37e-06	3.13e-05	CcSEcCtD
Mesalazine—Shock—Doxorubicin—hematologic cancer	5.36e-06	3.13e-05	CcSEcCtD
Mesalazine—Nervous system disorder—Doxorubicin—hematologic cancer	5.35e-06	3.12e-05	CcSEcCtD
Mesalazine—Thrombocytopenia—Doxorubicin—hematologic cancer	5.34e-06	3.12e-05	CcSEcCtD
Mesalazine—Pruritus—Prednisone—hematologic cancer	5.33e-06	3.11e-05	CcSEcCtD
Mesalazine—Insomnia—Epirubicin—hematologic cancer	5.33e-06	3.11e-05	CcSEcCtD
Mesalazine—Tachycardia—Doxorubicin—hematologic cancer	5.32e-06	3.11e-05	CcSEcCtD
Mesalazine—Skin disorder—Doxorubicin—hematologic cancer	5.3e-06	3.09e-05	CcSEcCtD
Mesalazine—Paraesthesia—Epirubicin—hematologic cancer	5.29e-06	3.09e-05	CcSEcCtD
Mesalazine—Hyperhidrosis—Doxorubicin—hematologic cancer	5.27e-06	3.08e-05	CcSEcCtD
Mesalazine—Dyspnoea—Epirubicin—hematologic cancer	5.25e-06	3.07e-05	CcSEcCtD
Mesalazine—Somnolence—Epirubicin—hematologic cancer	5.24e-06	3.06e-05	CcSEcCtD
Mesalazine—Anorexia—Doxorubicin—hematologic cancer	5.2e-06	3.03e-05	CcSEcCtD
Mesalazine—Feeling abnormal—Methotrexate—hematologic cancer	5.19e-06	3.03e-05	CcSEcCtD
Mesalazine—Dyspepsia—Epirubicin—hematologic cancer	5.19e-06	3.03e-05	CcSEcCtD
Mesalazine—Diarrhoea—Prednisone—hematologic cancer	5.15e-06	3.01e-05	CcSEcCtD
Mesalazine—Gastrointestinal pain—Methotrexate—hematologic cancer	5.15e-06	3.01e-05	CcSEcCtD
Mesalazine—Nausea—Betamethasone—hematologic cancer	5.14e-06	3e-05	CcSEcCtD
Mesalazine—Nausea—Dexamethasone—hematologic cancer	5.14e-06	3e-05	CcSEcCtD
Mesalazine—Decreased appetite—Epirubicin—hematologic cancer	5.12e-06	2.99e-05	CcSEcCtD
Mesalazine—Hypotension—Doxorubicin—hematologic cancer	5.09e-06	2.97e-05	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Epirubicin—hematologic cancer	5.09e-06	2.97e-05	CcSEcCtD
Mesalazine—Fatigue—Epirubicin—hematologic cancer	5.08e-06	2.97e-05	CcSEcCtD
Mesalazine—Constipation—Epirubicin—hematologic cancer	5.04e-06	2.94e-05	CcSEcCtD
Mesalazine—Pain—Epirubicin—hematologic cancer	5.04e-06	2.94e-05	CcSEcCtD
Mesalazine—Urticaria—Methotrexate—hematologic cancer	5e-06	2.92e-05	CcSEcCtD
Mesalazine—Dizziness—Prednisone—hematologic cancer	4.98e-06	2.91e-05	CcSEcCtD
Mesalazine—Abdominal pain—Methotrexate—hematologic cancer	4.98e-06	2.91e-05	CcSEcCtD
Mesalazine—Body temperature increased—Methotrexate—hematologic cancer	4.98e-06	2.91e-05	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	4.97e-06	2.9e-05	CcSEcCtD
Mesalazine—Insomnia—Doxorubicin—hematologic cancer	4.93e-06	2.88e-05	CcSEcCtD
Mesalazine—Paraesthesia—Doxorubicin—hematologic cancer	4.9e-06	2.86e-05	CcSEcCtD
Mesalazine—Dyspnoea—Doxorubicin—hematologic cancer	4.86e-06	2.84e-05	CcSEcCtD
Mesalazine—Feeling abnormal—Epirubicin—hematologic cancer	4.86e-06	2.83e-05	CcSEcCtD
Mesalazine—Somnolence—Doxorubicin—hematologic cancer	4.85e-06	2.83e-05	CcSEcCtD
Mesalazine—Gastrointestinal pain—Epirubicin—hematologic cancer	4.82e-06	2.81e-05	CcSEcCtD
Mesalazine—Dyspepsia—Doxorubicin—hematologic cancer	4.8e-06	2.8e-05	CcSEcCtD
Mesalazine—Vomiting—Prednisone—hematologic cancer	4.79e-06	2.8e-05	CcSEcCtD
Mesalazine—Rash—Prednisone—hematologic cancer	4.75e-06	2.77e-05	CcSEcCtD
Mesalazine—Dermatitis—Prednisone—hematologic cancer	4.75e-06	2.77e-05	CcSEcCtD
Mesalazine—Decreased appetite—Doxorubicin—hematologic cancer	4.74e-06	2.77e-05	CcSEcCtD
Mesalazine—Headache—Prednisone—hematologic cancer	4.72e-06	2.76e-05	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Doxorubicin—hematologic cancer	4.71e-06	2.75e-05	CcSEcCtD
Mesalazine—Fatigue—Doxorubicin—hematologic cancer	4.7e-06	2.74e-05	CcSEcCtD
Mesalazine—Urticaria—Epirubicin—hematologic cancer	4.68e-06	2.73e-05	CcSEcCtD
Mesalazine—Constipation—Doxorubicin—hematologic cancer	4.66e-06	2.72e-05	CcSEcCtD
Mesalazine—Pain—Doxorubicin—hematologic cancer	4.66e-06	2.72e-05	CcSEcCtD
Mesalazine—Body temperature increased—Epirubicin—hematologic cancer	4.66e-06	2.72e-05	CcSEcCtD
Mesalazine—Abdominal pain—Epirubicin—hematologic cancer	4.66e-06	2.72e-05	CcSEcCtD
Mesalazine—Hypersensitivity—Methotrexate—hematologic cancer	4.64e-06	2.71e-05	CcSEcCtD
Mesalazine—Asthenia—Methotrexate—hematologic cancer	4.52e-06	2.64e-05	CcSEcCtD
Mesalazine—Feeling abnormal—Doxorubicin—hematologic cancer	4.49e-06	2.62e-05	CcSEcCtD
Mesalazine—Nausea—Prednisone—hematologic cancer	4.48e-06	2.61e-05	CcSEcCtD
Mesalazine—Gastrointestinal pain—Doxorubicin—hematologic cancer	4.46e-06	2.6e-05	CcSEcCtD
Mesalazine—Pruritus—Methotrexate—hematologic cancer	4.45e-06	2.6e-05	CcSEcCtD
Mesalazine—Hypersensitivity—Epirubicin—hematologic cancer	4.34e-06	2.53e-05	CcSEcCtD
Mesalazine—Urticaria—Doxorubicin—hematologic cancer	4.33e-06	2.53e-05	CcSEcCtD
Mesalazine—Body temperature increased—Doxorubicin—hematologic cancer	4.31e-06	2.52e-05	CcSEcCtD
Mesalazine—Abdominal pain—Doxorubicin—hematologic cancer	4.31e-06	2.52e-05	CcSEcCtD
Mesalazine—Diarrhoea—Methotrexate—hematologic cancer	4.31e-06	2.51e-05	CcSEcCtD
Mesalazine—Asthenia—Epirubicin—hematologic cancer	4.23e-06	2.47e-05	CcSEcCtD
Mesalazine—Pruritus—Epirubicin—hematologic cancer	4.17e-06	2.43e-05	CcSEcCtD
Mesalazine—Dizziness—Methotrexate—hematologic cancer	4.16e-06	2.43e-05	CcSEcCtD
Mesalazine—Diarrhoea—Epirubicin—hematologic cancer	4.03e-06	2.35e-05	CcSEcCtD
Mesalazine—Hypersensitivity—Doxorubicin—hematologic cancer	4.02e-06	2.34e-05	CcSEcCtD
Mesalazine—Vomiting—Methotrexate—hematologic cancer	4e-06	2.34e-05	CcSEcCtD
Mesalazine—Rash—Methotrexate—hematologic cancer	3.97e-06	2.32e-05	CcSEcCtD
Mesalazine—Dermatitis—Methotrexate—hematologic cancer	3.97e-06	2.32e-05	CcSEcCtD
Mesalazine—Headache—Methotrexate—hematologic cancer	3.94e-06	2.3e-05	CcSEcCtD
Mesalazine—Asthenia—Doxorubicin—hematologic cancer	3.91e-06	2.28e-05	CcSEcCtD
Mesalazine—Dizziness—Epirubicin—hematologic cancer	3.9e-06	2.27e-05	CcSEcCtD
Mesalazine—Pruritus—Doxorubicin—hematologic cancer	3.86e-06	2.25e-05	CcSEcCtD
Mesalazine—Vomiting—Epirubicin—hematologic cancer	3.75e-06	2.19e-05	CcSEcCtD
Mesalazine—Nausea—Methotrexate—hematologic cancer	3.74e-06	2.18e-05	CcSEcCtD
Mesalazine—Diarrhoea—Doxorubicin—hematologic cancer	3.73e-06	2.18e-05	CcSEcCtD
Mesalazine—Rash—Epirubicin—hematologic cancer	3.72e-06	2.17e-05	CcSEcCtD
Mesalazine—Dermatitis—Epirubicin—hematologic cancer	3.71e-06	2.17e-05	CcSEcCtD
Mesalazine—Headache—Epirubicin—hematologic cancer	3.69e-06	2.15e-05	CcSEcCtD
Mesalazine—Dizziness—Doxorubicin—hematologic cancer	3.61e-06	2.1e-05	CcSEcCtD
Mesalazine—Nausea—Epirubicin—hematologic cancer	3.5e-06	2.04e-05	CcSEcCtD
Mesalazine—Vomiting—Doxorubicin—hematologic cancer	3.47e-06	2.02e-05	CcSEcCtD
Mesalazine—Rash—Doxorubicin—hematologic cancer	3.44e-06	2.01e-05	CcSEcCtD
Mesalazine—Dermatitis—Doxorubicin—hematologic cancer	3.43e-06	2e-05	CcSEcCtD
Mesalazine—Headache—Doxorubicin—hematologic cancer	3.42e-06	1.99e-05	CcSEcCtD
Mesalazine—Nausea—Doxorubicin—hematologic cancer	3.24e-06	1.89e-05	CcSEcCtD
Mesalazine—PPARG—Metabolism—PIK3CD—hematologic cancer	1.88e-06	1.65e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—CDKN1B—hematologic cancer	1.87e-06	1.63e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—IFNG—hematologic cancer	1.87e-06	1.63e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—FOXO1—hematologic cancer	1.87e-06	1.63e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PDGFRB—hematologic cancer	1.86e-06	1.63e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—ALB—hematologic cancer	1.86e-06	1.62e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—MDM2—hematologic cancer	1.86e-06	1.62e-05	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—HRAS—hematologic cancer	1.85e-06	1.62e-05	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—IL6—hematologic cancer	1.85e-06	1.61e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—MTOR—hematologic cancer	1.84e-06	1.61e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—PIK3CB—hematologic cancer	1.84e-06	1.61e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—IL1B—hematologic cancer	1.84e-06	1.61e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—CD4—hematologic cancer	1.84e-06	1.61e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PDGFRA—hematologic cancer	1.83e-06	1.6e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—FGFR3—hematologic cancer	1.83e-06	1.6e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—IL2RA—hematologic cancer	1.83e-06	1.6e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—IL2—hematologic cancer	1.83e-06	1.6e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—JAK1—hematologic cancer	1.83e-06	1.6e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PRKCG—hematologic cancer	1.83e-06	1.6e-05	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—PIK3CA—hematologic cancer	1.82e-06	1.59e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MAPK14—hematologic cancer	1.81e-06	1.59e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—TERT—hematologic cancer	1.81e-06	1.58e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—MTOR—hematologic cancer	1.81e-06	1.58e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—PIK3CB—hematologic cancer	1.81e-06	1.58e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CD4—hematologic cancer	1.8e-06	1.58e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—MTHFR—hematologic cancer	1.79e-06	1.56e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—JUN—hematologic cancer	1.78e-06	1.56e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—ESR1—hematologic cancer	1.78e-06	1.55e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PIK3R1—hematologic cancer	1.78e-06	1.55e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	1.77e-06	1.55e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PDGFB—hematologic cancer	1.77e-06	1.54e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—FN1—hematologic cancer	1.76e-06	1.54e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—HRAS—hematologic cancer	1.75e-06	1.53e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—GSTP1—hematologic cancer	1.75e-06	1.53e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—NFKBIA—hematologic cancer	1.74e-06	1.52e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—BAD—hematologic cancer	1.74e-06	1.52e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—CDKN1B—hematologic cancer	1.73e-06	1.51e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—TSC2—hematologic cancer	1.73e-06	1.51e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—CDKN1A—hematologic cancer	1.73e-06	1.51e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—PTEN—hematologic cancer	1.72e-06	1.51e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—NOTCH1—hematologic cancer	1.72e-06	1.5e-05	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—AKT1—hematologic cancer	1.7e-06	1.49e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CDKN1B—hematologic cancer	1.7e-06	1.48e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—MTHFR—hematologic cancer	1.69e-06	1.48e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	1.69e-06	1.48e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—TERT—hematologic cancer	1.69e-06	1.48e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—HLA-A—hematologic cancer	1.69e-06	1.48e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—MAPK8—hematologic cancer	1.68e-06	1.47e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CD80—hematologic cancer	1.68e-06	1.47e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—KIT—hematologic cancer	1.68e-06	1.47e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PIK3CG—hematologic cancer	1.68e-06	1.47e-05	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—HRAS—hematologic cancer	1.68e-06	1.47e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—IL6—hematologic cancer	1.67e-06	1.46e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—IL1B—hematologic cancer	1.67e-06	1.46e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—FGFR3—hematologic cancer	1.66e-06	1.45e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—IL2—hematologic cancer	1.66e-06	1.45e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—ABCB1—hematologic cancer	1.65e-06	1.44e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PTPN11—hematologic cancer	1.65e-06	1.44e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PDGFB—hematologic cancer	1.65e-06	1.44e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MAPK14—hematologic cancer	1.64e-06	1.44e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—EP300—hematologic cancer	1.64e-06	1.44e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PIK3CB—hematologic cancer	1.64e-06	1.43e-05	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—AKT1—hematologic cancer	1.64e-06	1.43e-05	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—PIK3CA—hematologic cancer	1.62e-06	1.41e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—JUN—hematologic cancer	1.61e-06	1.41e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—ESR1—hematologic cancer	1.61e-06	1.41e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—TSC2—hematologic cancer	1.61e-06	1.41e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—NCOR1—hematologic cancer	1.6e-06	1.4e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—GSTM1—hematologic cancer	1.6e-06	1.4e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CREB1—hematologic cancer	1.6e-06	1.4e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—SRC—hematologic cancer	1.6e-06	1.4e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—CDKN1A—hematologic cancer	1.59e-06	1.39e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—FN1—hematologic cancer	1.59e-06	1.39e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—PTEN—hematologic cancer	1.59e-06	1.39e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—BRAF—hematologic cancer	1.58e-06	1.38e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—BAD—hematologic cancer	1.57e-06	1.38e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—NFKBIA—hematologic cancer	1.57e-06	1.38e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.57e-06	1.38e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CCL2—hematologic cancer	1.57e-06	1.37e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CDKN1A—hematologic cancer	1.56e-06	1.37e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—PTEN—hematologic cancer	1.56e-06	1.36e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—IL6R—hematologic cancer	1.56e-06	1.36e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—NOTCH1—hematologic cancer	1.56e-06	1.36e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CREBBP—hematologic cancer	1.56e-06	1.36e-05	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—MAPK3—hematologic cancer	1.56e-06	1.36e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—FGFR3—hematologic cancer	1.55e-06	1.35e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—AKT1—hematologic cancer	1.54e-06	1.35e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—STAT3—hematologic cancer	1.54e-06	1.35e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—NRAS—hematologic cancer	1.54e-06	1.34e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—MAPK8—hematologic cancer	1.53e-06	1.34e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CD80—hematologic cancer	1.53e-06	1.34e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—KIT—hematologic cancer	1.52e-06	1.33e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PIK3CG—hematologic cancer	1.52e-06	1.33e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—EP300—hematologic cancer	1.52e-06	1.33e-05	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—MYC—hematologic cancer	1.52e-06	1.32e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PIK3CG—hematologic cancer	1.5e-06	1.31e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PTPN11—hematologic cancer	1.5e-06	1.31e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—EP300—hematologic cancer	1.49e-06	1.3e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MAP2K1—hematologic cancer	1.49e-06	1.3e-05	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—AKT1—hematologic cancer	1.48e-06	1.3e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PIK3CD—hematologic cancer	1.48e-06	1.29e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—SRC—hematologic cancer	1.47e-06	1.29e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—MAPK3—hematologic cancer	1.47e-06	1.29e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—BAD—hematologic cancer	1.47e-06	1.28e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—NOTCH1—hematologic cancer	1.45e-06	1.27e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CREB1—hematologic cancer	1.45e-06	1.27e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—SRC—hematologic cancer	1.45e-06	1.27e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—BRAF—hematologic cancer	1.43e-06	1.25e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—CD80—hematologic cancer	1.42e-06	1.25e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—KIT—hematologic cancer	1.42e-06	1.24e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—STAT3—hematologic cancer	1.42e-06	1.24e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CCL2—hematologic cancer	1.42e-06	1.24e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—NRAS—hematologic cancer	1.42e-06	1.24e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PTEN—hematologic cancer	1.42e-06	1.24e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—MTHFR—hematologic cancer	1.42e-06	1.24e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—IL6R—hematologic cancer	1.42e-06	1.24e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—FGF2—hematologic cancer	1.42e-06	1.24e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CREBBP—hematologic cancer	1.41e-06	1.24e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PTPN11—hematologic cancer	1.4e-06	1.22e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—STAT3—hematologic cancer	1.4e-06	1.22e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PIK3R1—hematologic cancer	1.4e-06	1.22e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—NRAS—hematologic cancer	1.39e-06	1.22e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—CREBBP—hematologic cancer	1.39e-06	1.22e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—MAPK3—hematologic cancer	1.36e-06	1.19e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—JAK2—hematologic cancer	1.36e-06	1.19e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—CREB1—hematologic cancer	1.35e-06	1.18e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—EP300—hematologic cancer	1.35e-06	1.18e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MAP2K1—hematologic cancer	1.35e-06	1.18e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PIK3CD—hematologic cancer	1.34e-06	1.17e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—BRAF—hematologic cancer	1.34e-06	1.17e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—MAPK3—hematologic cancer	1.33e-06	1.17e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MDM2—hematologic cancer	1.32e-06	1.16e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—KRAS—hematologic cancer	1.32e-06	1.16e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—MYC—hematologic cancer	1.32e-06	1.15e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—IL6R—hematologic cancer	1.32e-06	1.15e-05	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—AKT1—hematologic cancer	1.32e-06	1.15e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PIK3CD—hematologic cancer	1.32e-06	1.15e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—CREBBP—hematologic cancer	1.32e-06	1.15e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—TGFB1—hematologic cancer	1.32e-06	1.15e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—ALB—hematologic cancer	1.3e-06	1.14e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MTOR—hematologic cancer	1.29e-06	1.13e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PIK3CB—hematologic cancer	1.29e-06	1.13e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—FGF2—hematologic cancer	1.28e-06	1.12e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PIK3R1—hematologic cancer	1.27e-06	1.11e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—MAP2K1—hematologic cancer	1.26e-06	1.1e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PIK3CD—hematologic cancer	1.25e-06	1.09e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.25e-06	1.09e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PIK3R1—hematologic cancer	1.25e-06	1.09e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—JAK2—hematologic cancer	1.23e-06	1.08e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—KRAS—hematologic cancer	1.22e-06	1.07e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—PIK3CA—hematologic cancer	1.21e-06	1.06e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CDKN1B—hematologic cancer	1.21e-06	1.06e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MDM2—hematologic cancer	1.2e-06	1.05e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—KRAS—hematologic cancer	1.2e-06	1.05e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—FGF2—hematologic cancer	1.2e-06	1.05e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PIK3CG—hematologic cancer	1.19e-06	1.04e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CASP3—hematologic cancer	1.18e-06	1.04e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—IL2—hematologic cancer	1.18e-06	1.03e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PIK3R1—hematologic cancer	1.18e-06	1.03e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PIK3CB—hematologic cancer	1.17e-06	1.02e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MTOR—hematologic cancer	1.17e-06	1.02e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CCND1—hematologic cancer	1.15e-06	1.01e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—JUN—hematologic cancer	1.15e-06	1.01e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PIK3CB—hematologic cancer	1.15e-06	1.01e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—JAK2—hematologic cancer	1.15e-06	1e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—HRAS—hematologic cancer	1.12e-06	9.82e-06	CbGpPWpGaD
Mesalazine—CHUK—Disease—PIK3CA—hematologic cancer	1.12e-06	9.8e-06	CbGpPWpGaD
Mesalazine—PTGS2—Disease—MDM2—hematologic cancer	1.12e-06	9.79e-06	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CDKN1A—hematologic cancer	1.12e-06	9.75e-06	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PTEN—hematologic cancer	1.11e-06	9.73e-06	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—CREBBP—hematologic cancer	1.1e-06	9.65e-06	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—PIK3CA—hematologic cancer	1.1e-06	9.63e-06	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CDKN1B—hematologic cancer	1.1e-06	9.58e-06	CbGpPWpGaD
Mesalazine—PTGS2—Disease—MTOR—hematologic cancer	1.09e-06	9.53e-06	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PIK3CB—hematologic cancer	1.09e-06	9.53e-06	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MAPK8—hematologic cancer	1.09e-06	9.52e-06	CbGpPWpGaD
Mesalazine—PTGS2—Disease—CD4—hematologic cancer	1.09e-06	9.51e-06	CbGpPWpGaD
Mesalazine—CHUK—Immune System—IL6—hematologic cancer	1.08e-06	9.4e-06	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CASP3—hematologic cancer	1.07e-06	9.39e-06	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—IL2—hematologic cancer	1.07e-06	9.38e-06	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—EP300—hematologic cancer	1.06e-06	9.28e-06	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—AKT1—hematologic cancer	1.05e-06	9.19e-06	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PIK3CD—hematologic cancer	1.05e-06	9.15e-06	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CCND1—hematologic cancer	1.05e-06	9.14e-06	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—JUN—hematologic cancer	1.04e-06	9.12e-06	CbGpPWpGaD
Mesalazine—CHUK—Disease—HRAS—hematologic cancer	1.04e-06	9.07e-06	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—ALB—hematologic cancer	1.03e-06	9.04e-06	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—SRC—hematologic cancer	1.03e-06	9.03e-06	CbGpPWpGaD
Mesalazine—PTGS2—Disease—CDKN1B—hematologic cancer	1.02e-06	8.94e-06	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—HRAS—hematologic cancer	1.02e-06	8.91e-06	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CDKN1A—hematologic cancer	1.01e-06	8.84e-06	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PTEN—hematologic cancer	1.01e-06	8.82e-06	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—VEGFA—hematologic cancer	1.01e-06	8.79e-06	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PIK3CA—hematologic cancer	1e-06	8.75e-06	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—STAT3—hematologic cancer	9.96e-07	8.7e-06	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PTEN—hematologic cancer	9.93e-07	8.68e-06	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—NRAS—hematologic cancer	9.93e-07	8.68e-06	CbGpPWpGaD
Mesalazine—CHUK—Disease—IL6—hematologic cancer	9.93e-07	8.68e-06	CbGpPWpGaD
Mesalazine—CHUK—Immune System—AKT1—hematologic cancer	9.92e-07	8.67e-06	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PIK3R1—hematologic cancer	9.89e-07	8.64e-06	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MAPK8—hematologic cancer	9.88e-07	8.63e-06	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—IL6—hematologic cancer	9.75e-07	8.53e-06	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—EP300—hematologic cancer	9.63e-07	8.42e-06	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MAPK3—hematologic cancer	9.51e-07	8.32e-06	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—EP300—hematologic cancer	9.47e-07	8.28e-06	CbGpPWpGaD
Mesalazine—PTGS2—Disease—CDKN1A—hematologic cancer	9.44e-07	8.25e-06	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PTEN—hematologic cancer	9.42e-07	8.23e-06	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—SRC—hematologic cancer	9.36e-07	8.18e-06	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MYC—hematologic cancer	9.25e-07	8.09e-06	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—TGFB1—hematologic cancer	9.23e-07	8.07e-06	CbGpPWpGaD
Mesalazine—CHUK—Disease—AKT1—hematologic cancer	9.16e-07	8.01e-06	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PIK3CB—hematologic cancer	9.13e-07	7.98e-06	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—VEGFA—hematologic cancer	9.12e-07	7.97e-06	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—STAT3—hematologic cancer	9.03e-07	7.89e-06	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—NRAS—hematologic cancer	9.01e-07	7.87e-06	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—AKT1—hematologic cancer	9e-07	7.87e-06	CbGpPWpGaD
Mesalazine—PTGS2—Disease—EP300—hematologic cancer	8.98e-07	7.85e-06	CbGpPWpGaD
Mesalazine—PTGS2—Disease—SRC—hematologic cancer	8.73e-07	7.63e-06	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MAPK3—hematologic cancer	8.63e-07	7.54e-06	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—KRAS—hematologic cancer	8.55e-07	7.47e-06	CbGpPWpGaD
Mesalazine—PTGS2—Disease—STAT3—hematologic cancer	8.42e-07	7.36e-06	CbGpPWpGaD
Mesalazine—PTGS2—Disease—NRAS—hematologic cancer	8.4e-07	7.34e-06	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MYC—hematologic cancer	8.39e-07	7.33e-06	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—TGFB1—hematologic cancer	8.37e-07	7.32e-06	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—AKT1—hematologic cancer	8.17e-07	7.14e-06	CbGpPWpGaD
Mesalazine—PTGS2—Disease—MAPK3—hematologic cancer	8.05e-07	7.03e-06	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PTEN—hematologic cancer	7.89e-07	6.89e-06	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PIK3CA—hematologic cancer	7.85e-07	6.87e-06	CbGpPWpGaD
Mesalazine—PTGS2—Disease—MYC—hematologic cancer	7.83e-07	6.84e-06	CbGpPWpGaD
Mesalazine—PTGS2—Disease—TGFB1—hematologic cancer	7.81e-07	6.82e-06	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—KRAS—hematologic cancer	7.75e-07	6.78e-06	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—TP53—hematologic cancer	7.6e-07	6.64e-06	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—EP300—hematologic cancer	7.52e-07	6.57e-06	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—HRAS—hematologic cancer	7.27e-07	6.35e-06	CbGpPWpGaD
Mesalazine—PTGS2—Disease—KRAS—hematologic cancer	7.23e-07	6.32e-06	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PIK3CA—hematologic cancer	7.12e-07	6.23e-06	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PIK3CA—hematologic cancer	7.01e-07	6.13e-06	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—IL6—hematologic cancer	6.95e-07	6.08e-06	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—TP53—hematologic cancer	6.89e-07	6.02e-06	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PIK3CA—hematologic cancer	6.64e-07	5.81e-06	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—HRAS—hematologic cancer	6.59e-07	5.76e-06	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—AKT1—hematologic cancer	6.42e-07	5.61e-06	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—IL6—hematologic cancer	6.31e-07	5.51e-06	CbGpPWpGaD
Mesalazine—PTGS2—Disease—HRAS—hematologic cancer	6.15e-07	5.37e-06	CbGpPWpGaD
Mesalazine—PTGS2—Disease—IL6—hematologic cancer	5.88e-07	5.14e-06	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—AKT1—hematologic cancer	5.82e-07	5.09e-06	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—AKT1—hematologic cancer	5.73e-07	5.01e-06	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PIK3CA—hematologic cancer	5.56e-07	4.86e-06	CbGpPWpGaD
Mesalazine—PTGS2—Disease—AKT1—hematologic cancer	5.43e-07	4.74e-06	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—AKT1—hematologic cancer	4.55e-07	3.97e-06	CbGpPWpGaD
